Synthesis of new alkylaminooxysterols with potent cell differentiating activities: Identification of leads for the treatment of cancer and neurodegenerative diseases

Journal of Medicinal Chemistry

Volumn 52, Issue 23, 2009, Pages 7765-7777

  De Medina, Philippe ^a   Paillasse, Michael R ^a   Payre, Bruno ^a   Silvente Poirot, Sandrine ^a   Poirot, Marc ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5,6ALPHA EPOXYANDROSTAN 3BETA,17BETA DIOL; 5,6ALPHA EPOXYCHOLEST 7 EN 3BETA OL; 5,6ALPHA EPOXYCHOLESTAN 3BETA ACETATE; 5,6ALPHA EPOXYCHOLESTAN 3BETA BUTYRATE; 5,6ALPHA EPOXYCHOLESTAN 3BETA OL; 5,6ALPHA EPOXYSTIGMASTAN 3BETA OL; 5ALPHA HYDROXY 6BETA (4 AMINOBUTYLAMINO)CHOLESTAN 3BETA OL; 5ALPHA HYDROXY 6BETA [2 (1H IMIDAZOL 4 YL)ETHYLAMINO]ANDROSTAN 3BETA, 17 DIOL; 5ALPHA HYDROXY 6BETA [2 (1H IMIDAZOL 4 YL)ETHYLAMINO]CHOLEST 7 EN 3BETA OL; 5ALPHA HYDROXY 6BETA [2 (1H IMIDAZOL 4 YL)ETHYLAMINO]CHOLESTAN 3BETA ACETATE; 5ALPHA HYDROXY 6BETA [2 (1H IMIDAZOL 4 YL)ETHYLAMINO]CHOLESTAN 3BETA BUTYRATE; 5ALPHA HYDROXY 6BETA [2 (1H IMIDAZOL 4 YL)ETHYLAMINO]CHOLESTAN 3BETA OL; 5ALPHA HYDROXY 6BETA [4 (2 AMINOETHYL)IMIDAZOL 1 YL]CHOLESTAN 3BETA OL; ANTINEOPLASTIC AGENT; DENDROGENIN A; DENDROGENIN B; EPOXIDE; HISTAMINE; N 1,N 3 DI TERT BUTYLOXYCARBONYL N 3 (3 CYANOPROPYL) 1,3 DIAMINOPROPANE; N 1,N 4 DI TERT BUTYLOXYCARBONYLSPERMIDINE; N 1,N 8 DI TERT BUTYLOXYCARBONYLSPERMIDINE; N 3 (2 CYANOPROPYL) 1,3 DIAMINOPROPANE; N 4 (2 CYANOETHYL) 1,4 DIAMINOBUTANE; N 4,N 8 DI TERT BUTYLOXYCARBONYL N4 (2 CYANOETHYL) 1,4 DIAMINOBUTANE; N 4,N 8 DI TERT BUTYLOXYCARBONYLSPERMIDINE; PUTRESCINE; SPERMIDINE; SPERMINE; STEROL DERIVATIVE; UNCLASSIFIED DRUG;

AMINOLYSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ACTIVATION; CELL DEATH; CELL DIFFERENTIATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DENDRITE; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG SYNTHESIS; GROWTH REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; PLURIPOTENT STEM CELL;

AMINES; ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; DENDRITES; DRUG DISCOVERY; HUMANS; MICE; NEOPLASMS; NEURODEGENERATIVE DISEASES; STEREOISOMERISM; STEROLS;

EID: 72249094961     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901063e     Document Type: Article

References (45)

1. Sutherland, R. L.; Foo, M. S. Differential binding of antiestrogens by rat uterine and chick oviduct cytosol. Biochem. Biophys. Res. Commun. 1979, 91, 183-191. (Pubitemid 10183359)
2. Jordan, V. C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J. Med. Chem. 2003, 46, 883-908. (Pubitemid 36423135)
3. Jordan, V. C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J. Med. Chem. 2003, 46, 1081-1111 (Pubitemid 36428213)
4. Kedjouar, B.; de Medina, P.; Oulad-Abdelghani, M.; Payre, B.; Silvente-Poirot, S.; Favre, G.; Faye, J. C.; Poirot, M. Molecular characterization of the microsomal tamoxifen binding site. J. Biol. Chem. 2004, 279, 34048-34061. (Pubitemid 39063057)
5. Poirot, M.; De Medina, P.; Delarue, F.; Perie, J. J.; Klaebe, A.; Faye, J. C. Synthesis, binding and structure-affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS). Bioorg. Med. Chem. 2000, 8, 2007-2016.
6. Kedjouar, B.; Daunes, S.; Vilner, B. J.; Bowen, W. D.; Klaebe, A.; Faye, J. C.; Poirot, M. Structural similitudes between cytotoxic antiestrogen-binding site (AEBS) ligands and cytotoxic sigma receptor ligands. Evidence for a relationship between cytotoxicity and affinity for AEBS or sigma-2 receptor but not for sigma-1 receptor. Biochem. Pharmacol. 1999, 58, 1927-1939.
7. Delarue, F.; Kedjouar, B.; Mesange, F.; Bayard, F.; Faye, J. C.; Poirot,M.Modifications of benzylphenoxy ethanamine antiestrogen molecules: influence affinity for antiestrogenbinding site (AEBS) and cell cytotoxicity. Biochem. Pharmacol. 1999, 57, 657-661.
8. van denKoedijk, C. D.;Govers,R.M.;Thijssen, J. H.;Blankenstein, M. A. Species specificity of triphenylethylene derivatives and of compounds with a steroidal backbone for human and rat liver antioestrogen binding site (AEBS). Biochem. Pharmacol. 1993, 46, 1870-1872.
9. Watts, C. K.; Sutherland, R. L. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites. Mol. Pharmacol. 1987, 31, 541-551.
10. de Medina, P.; Payre, B.; Boubekeur, N.; Bertrand-Michel, J.; Terce, F.; Silvente-Poirot, S.; Poirot, M. Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism. Cell Death Differ. 2009, 16, 1372-1384.
11. Burke, P. J.; Kalet, B. T.; Koch, T. H. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells. J. Med. Chem. 2004, 47, 6509-6518
12. Jones, J. A.; Albright, K. D.; Christen, R. D.; Howell, S. B.; McClay, E. F. Synergy between tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogenbinding sites. Cancer Res. 1997, 57, 2657-2660.
13. Teo, C. C.; Kon, O. L.; Sim, K. Y.; Ng, S. C. Synthesis of 2-(p-chlorobenzyl)-3-aryl-6-methoxybenzofurans as selective ligands for antiestrogen-binding sites. Effects on cell proliferation and cholesterol synthesis. J. Med. Chem. 1992, 35, 1330-1339.
14. Fargin, A.; Bayard, F.; Faye, J. C.; Traore, M.; Poirot, M.; Klaebe, A.; Perie, J. J. Further evidence for a biological role of antiestrogen-binding sites in mediating the growth inhibitory action of diphenylmethane derivatives. Chem.-Biol. Interact 1988, 66, 101-109.
15. Brandes, L. J.; Gerrard, J. M.; Bogdanovic, R. P.; Lint, D. W.; Reid, R. E.; LaBella, F. S. Correlation of the antiproliferative action of diphenylmethane-derivative antiestrogen binding site ligands with antagonism of histamine binding but not of protein kinase C-mediated phosphorylation. Cancer Res. 1988, 48, 3954-3958.
16. Raghavan, D.; Brandes, L. J.; Klapp, K.; Snyder, T.; Styles, E.; Tsao-Wei, D.; Lieskovsky, G.; Quinn, D. I.; Ramsey, E. W. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. J. Urol. 2005, 174, 1808-1813. (Pubitemid 41546946)
17. Reyno, L.; Seymour, L.; Tu, D.; Dent, S.; Gelmon, K.; Walley, B.; Pluzanska, A.; Gorbunova, V.; Garin, A.; Jassem, J.; Pienkowski, T.; Dancey, J.; Pearce, L.; MacNeil, M.; Marlin, S.; Lebwohl, D.; Voi, M.; Pritchard, K. Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/ recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J. Clin. Oncol. 2004, 22, 269-276. (Pubitemid 41095091)
18. Khoo,K.; Brandes,L.;Reyno,L.;Arnold,A.;Dent, S.;Vandenberg, T.; Lebwohl, D.; Fisher, B.; Eisenhauer, E. Phase II trial of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine 3 HCl and doxorubicin chemotherapy in metastatic breast cancer: a National Cancer Institute of Canada clinical trials group study. J. Clin. Oncol. 1999, 17, 3431-3437.
19. Brandes, L. J.; Bracken, S. P. The intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethamine · HCL, may potentiate doxorubicin in the treatment of metastatic breast cancer: results of a pilot study. Breast Cancer Res. Treat. 1998, 49, 61-68.
20. Brandes, L. J.; Bracken, S. P.; Ramsey, E. W. N,N-Diethyl-2-[4- (phenylmethyl)phenoxy]ethanamine in combination with cyclophosphamide: an active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer. J. Clin. Oncol. 1995, 13, 1398-1403.
21. Brandes, L. J.; Simons, K. J.; Bracken, S. P.; Warrington, R. C. Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl, in combination with various single antineoplastic agents. J. Clin. Oncol. 1994, 12, 1281-1290. (Pubitemid 24173945)
22. Mesange, F.; Sebbar, M.; Capdevielle, J.; Guillemot, J. C.; Ferrara, P.; Bayard, F.; Poirot, M.; Faye, J. C. Identification of two tamoxifen target proteins by photolabeling with 4-(2-morpholinoethoxy)benzophenone. Bioconjugate Chem. 2002, 13, 766-772.
23. Paul, R.; Silve, S.; De Nys, N.; Dupuy, P. H.; Bouteiller, C. L.; Rosenfeld, J.; Ferrara, P.; Le Fur, G.; Casellas, P.; Loison, G. Both the immunosuppressant SR31747 and the antiestrogen tamoxifen bind to an emopamil-insensitive site of mammalian delta8-delta7 sterol isomerase. J Pharmacol. Exp. Ther. 1998, 285, 1296-1302. (Pubitemid 28277932)
24. 3H]ifenprodil. Mol. Pharmacol. 1998, 54, 591-598.
25. Mesange, F.; Sebbar, M.; Kedjouar, B.; Capdevielle, J.; Guillemot, J. C.; Ferrara, P.; Bayard, F.; Delarue, F.; Faye, J. C.; Poirot, M. Microsomal epoxide hydrolase of rat liver is a subunit of theantioestrogen-binding site. Biochem. J. 1998, 334 (Part 1), 107-112. (Pubitemid 28420978)
26. Herman, G. E. Disorders of cholesterol biosynthesis: prototypic metabolic malformation syndromes. Hum. Mol. Genet. 2003, 12 (Spec. No. 1), R75-R88.
27. de Medina, P.; Silvente-Poirot, S.; Poirot, M. Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy 2009, 5, 1066-1067.
28. Payre, B.; de Medina, P.; Boubekeur, N.; Mhamdi, L.; Bertrand-Michel, J.; Terce, F.; Fourquaux, I.; Goudouneche, D.; Record, M.; Poirot, M.; Silvente-Poirot, S. Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Mol. Cancer Ther. 2008, 7, 3707-3718.
29. Schroepfer, G. J., Jr. Oxysterols: modulators of cholesterol metabolism and other processes. Physiol. Rev. 2000, 80, 361-554.
30. Brandes, L. J.; Macdonald, L. M.; Bogdanovic, R. P. Evidence that the antiestrogen binding site is a histamine or histamine-like receptor. Biochem. Biophys. Res. Commun. 1985, 126, 905-910.
31. Rainey, M. A.; Callaway, K.; Barnes, R.; Wilson, B.; Dalby, K. N. Proximity-induced catalysis by the protein kinase ERK2. J. Am. Chem. Soc. 2005, 127, 10494-10495.
32. Sevanian, A.; McLeod, L. L. Catalytic properties and inhibition of hepatic cholesterol-epoxide hydrolase. J. Biol.Chem. 1986, 261, 54-59.
33. Michaud, D. P.; Nashed, N. T.; Jerina, D. M. Stereoselective synthesis and solvolytic behavior of the isomeric 7-dehydrocholesterol 5,6-oxides. J. Org. Chem. 1985, 50, 1835-1840.
34. Chini, M.; Crotti, P.; Macchia, F. Metal salts as new catalysts for mild and efficient aminolysis of oxiranes. Tetrahedron Lett. 1990, 31, 4661-4664. (Pubitemid 20226237)
35. Laurenzana, A.; Petruccelli, L. A.; Pettersson, F.; Figueroa, M. E.; Melnick, A.; Baldwin, A. S.; Paoletti, F.; Miller, W. H., Jr. Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells. Cancer Res. 2009, 69, 55-64.
36. Zuckerman, S. H.; Surprenant, Y. M.; Tang, J. Synergistic effect of granulocyte-macrophage colony-stimulating factor and 1,25-dihydroxyvitamin D3 on the differentiation of the human monocytic cell line U937. Blood 1988, 71, 619-624. (Pubitemid 18102077)
37. Soprano, D. R.; Teets, B. W.; Soprano, K. J. Role of retinoic acid in the differentiation of embryonal carcinoma and embryonic stem cells. Vitam. Horm. 2007, 75, 69-95.
38. van der Heyden, M. A.; Defize, L. H. Twenty one years of P19 cells: what an embryonal carcinoma cell line taught us about cardiomyocyte differentiation. Cardiovasc. Res. 2003, 58, 292-302.
39. MacPherson, P. A.; Jones, S.; Pawson, P. A.; Marshall, K. C.; McBurney, M. W. P19 cells differentiate into glutamatergic and glutamate-responsive neurons in vitro. Neuroscience 1997, 80, 487-499.
40. Robson, L. G.; Dyall, S.; Sidloff, D.; Michael-Titus, A. T. Omega-3 polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurones throughout development and in aged animals. Neurobiol Aging, in press.
41. Zhang, X.;Geoffroy, P.;Miesch,M.; Julien-David,D.;Raul, F.; Aoude-Werner, D.; Marchioni, E. Gram-scale chromatographic purification of beta-sitosterol. Synthesis and characterization of beta-sitosterol oxides. Steroids 2005, 70, 886-895.
42. Bligh, E. G.; Dyer, W. J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37, 911-917.
43. Smit, M.; Leng, J.; Klemke, R. L. Assay for neurite outgrowth quantification. BioTechniques 2003, 35, 254-256.
44. Lee, J.; Kim, Y. S.; Park, D. Rosmarinic acid induces melanogenesis through protein kinase A activation signaling. Biochem. Pharmacol. 2007, 74, 960-968. (Pubitemid 47299088)
45. de Medina, P.; Payre, B. L.; Bernad, J.; Bosser, I.; Pipy, B.; Silvente-Poirot, S.; Favre, G.; Faye, J. C.; Poirot,M. Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. J. Pharmacol. Exp. Ther. 2004, 308, 1165-1173.